Skip to main content

Advertisement

SpringerLink
Log in

Glial S100B Protein Modulates Mutant Ataxin-1 Aggregation and Toxicity: TRTK12 Peptide, a Potential Candidate for SCA1 Therapy

  • Published:
The Cerebellum Aims and scope Submit manuscript

Abstract

Non-cell autonomous involvement of glial cells in the pathogenesis of polyglutamine diseases is gaining recognition in the ataxia field. We previously demonstrated that Purkinje cells (PCs) in polyglutamine disease spinocerebellar ataxia-1 (SCA1) contain cytoplasmic vacuoles rich in Bergmann glial protein S100B. The vacuolar formation in SCA1 PCs is accompanied with an abnormal morphology of dendritic spines. In addition, S100B messenger RNA (mRNA) expression levels are significantly high in the cerebella of asymptomatic SCA1 transgenic (Tg) mice and increase further with age when compared with the age-matched wild-type animals. This higher S100B mRNA expression positively correlates with an increase in the number of vacuoles. To further characterize the function of S100B in SCA1 pathology, we explored the effects of S100B protein on GFP-ataxin-1 (ATXN1) with expanded polyglutamines [82Q] in HEK stable cell line. Externally added S100B protein to these cells induced S100B-positive vacuoles similar to those seen in SCA1 PCs in vivo. Further, we found that both externally added and internally expressed S100B significantly reduced GFP-ATXN1[82Q] inclusion body formation. In contrast, the addition of S100B inhibitory peptide TRTK12 reversed S100B-mediated effects. Interestingly, in SCA1 Tg mice, PCs containing S100B vacuoles also showed the lack of nuclear inclusions, whereas PCs without vacuoles contained nuclear inclusions. Additionally, TRTK12 treatment reduced abnormal dendritic growth and morphology of PCs in cerebellar slice cultures prepared from SCA1 Tg mice. Moreover, intranasal administration of TRTK12 to SCA1 Tg mice reduced cerebellar S100B levels in the particulate fractions, and these mice displayed a significant improvement in their performance deficit on the Rotarod test. Taken together, our results suggest that glial S100B may augment degenerative changes in SCA1 PCs by modulating mutant ataxin-1 toxicity/solubility through an unknown signaling pathway.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8

Similar content being viewed by others

References

  1. Koeppen AH. The pathogenesis of spinocerebellar ataxia. Cerebellum. 2005;4:62–73.

    Article  PubMed  CAS  Google Scholar 

  2. Matilla-Dueñas A, Goold R, Giunti P. Clinical, genetic, molecular, and pathophysiological insights into spinocerebellar ataxia type 1. Cerebellum. 2008;7:106–14.

    Article  PubMed  Google Scholar 

  3. Orr HT, Zoghbi HY. Trinucleotide repeat disorders. Annu Rev Neurosci. 2007;30:575–621.

    Article  PubMed  CAS  Google Scholar 

  4. Banfi S, Servadio A, Chung MY, Kwiatkowski Jr TJ, McCall AE, Duvick LA, et al. Identification and characterization of the gene causing type 1 spinocerebellar ataxia. Nat Genet. 1994;7:513–20.

    Article  PubMed  CAS  Google Scholar 

  5. Duvick L, Barnes J, Ebner B, Agrawal S, Andresen M, Lim J, et al. SCA1-like disease in mice expressing wild-type ataxin-1 with a serine to aspartic acid replacement at residue 776. Neuron. 2010;67:929–35.

    Article  PubMed  CAS  Google Scholar 

  6. Burright EN, Clark HB, Servadio A, Matilla T, Feddersen RM, Yunis WS, et al. SCA-1 transgenic mice: a model for neurodegeneration caused by an expanded CAG trinucleotide repeat. Cell. 1995;82:937–48.

    Article  PubMed  CAS  Google Scholar 

  7. Skinner PJ, Vierra-Green CA, Clark HB, Zoghbi HY, Orr HT. Altered trafficking of membrane proteins in Purkinje cells of SCA1 transgenic mice. Am J Pathol. 2001;159:905–13.

    Article  PubMed  CAS  Google Scholar 

  8. Vig PJS, Lopez ME, Wei J, D’Souza DR, Subramony SH, Henegar J, et al. Glial S100B positive vacuoles in Purkinje cells: earliest morphological abnormality in SCA1 transgenic mice. J Neurol Sci [Turk]. 2006;23:166–74.

    Google Scholar 

  9. Vig PJ, Shao Q, Subramony SH, Lopez ME, Safaya E. Bergmann glial S100B activates myo-inositol monophosphatase 1 and co-localizes to Purkinje cell vacuoles in SCA1 transgenic mice. Cerebellum. 2009;8:231–44.

    Article  PubMed  CAS  Google Scholar 

  10. Donato R. Perspectives in S-100 protein biology. Cell Calcium. 1991;12:713–26.

    Article  PubMed  CAS  Google Scholar 

  11. Zimmer DB, Chaplin J, Baldwin A, Rast M. S100-mediated signal transduction in the nervous system and neurological diseases. Cell Mol Biol. 2005;51:201–14.

    PubMed  CAS  Google Scholar 

  12. Reeves RH, Yao J, Crowley MR, Buck S, Zhang X, Yarowsky P, et al. Astrocytosis and axonal proliferation in the hippocampus of S100b transgenic mice. Proc Natl Acad Sci USA. 1994;91:5359–63.

    Article  PubMed  CAS  Google Scholar 

  13. Huttunen HJ, Kuja-Panula J, Sorci G, Agneletti AL, Donato R, Rauvala H, et al. Coregulation of neurite outgrowth and cell survival by amphoterin and S100 proteins through receptor for advanced glycation end products (RAGE) activation. J Biol Chem. 2000;275:40096–105.

    Article  PubMed  CAS  Google Scholar 

  14. Rothermundt M, Peters M, Prehn JH, Arolt V. S100B in brain damage and neurodegeneration. Microsc Res Tech. 2003;60:614–32.

    Article  PubMed  CAS  Google Scholar 

  15. Winningham-Major F, Staecker JL, Barges SW, Coats S, VanElkik J. Neurite extension and neuronal survival activities of recombinant S100β proteins that differ in the content and position of cysteine residues. J Cell Biol. 1989;109:3064–71.

    Article  Google Scholar 

  16. Barger SW, VanEldik LJ, Mattson MP. S100β protects hippocampal neurons from damage induced by glucose deprivation. Brain Res. 1995;677:167–70.

    Article  PubMed  CAS  Google Scholar 

  17. Whitaker-Azmitia PM, Vingate M, Borella A, Gerlai R, Roder J, Azmitia EC. Transgenic mice overexpressing the neurotrophic factor S-100β show neuronal cytoskeletal and behavioral signs of altered aging processes: implications for Alzheimer’s disease and Down’s syndrome. Brain Res. 1997;776:51–60.

    Article  PubMed  CAS  Google Scholar 

  18. Griffin WS, Stanley LC, Ling C, White L, MacLeod V, Perrot LJ, et al. Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proc Natl Acad Sci USA. 1989;86:7611–5.

    Article  PubMed  CAS  Google Scholar 

  19. Kato K, Suzuki F, Kurobe N, Okajima K, Ogasawara N, Nagaya M, et al. Enhancement of S-100β protein in blood of patients with Down’s syndrome. J Mol Neurosci. 1990;2:109–13.

    Article  PubMed  CAS  Google Scholar 

  20. Donato R. Functional roles of S100 proteins, calcium binding proteins of the EF-hand type. Biochim Biophys Acta. 1999;1450:191–231.

    Article  PubMed  CAS  Google Scholar 

  21. McClintock KA, Shaw GS. A logical sequence search for S100B target proteins. Protein Sci. 2000;10:2043–6.

    Article  Google Scholar 

  22. Wilder PT, Lin J, Bair CL, Charpentier TH, Yang D, Liriano M, et al. Recognition of the tumor suppressor protein p53 and other protein targets by the calcium-binding protein S100B. Biochim Biophys Acta. 2006;1763:1284–97.

    Article  PubMed  CAS  Google Scholar 

  23. Yamada K, Watanabe M. Cytodifferentiation of Bergmann glia and its relationship with Purkinje cell. Anat Sci Int. 2002;2:94–108.

    Article  Google Scholar 

  24. Hoogland TM, Kuhn B. Recent developments in the understanding of astrocyte function in the cerebellum in vivo. Cerebellum. 2010;9:264–71.

    Article  PubMed  Google Scholar 

  25. Delaney CL, Brenner M, Messing A. Conditional ablation of cerebellar astrocytes in postnatal transgenic mice. J Neurosci. 1996;16:6908–18.

    PubMed  CAS  Google Scholar 

  26. Shiwaku H, Yoshimura N, Tamura T, Sone M, Ogishima S, Watase K, et al. Suppression of the novel ER protein Maxer by mutant ataxin-1 in Bergman glia contributes to non-cell-autonomous toxicity. EMBO J. 2010;29:2446–60.

    Article  PubMed  CAS  Google Scholar 

  27. Custer SK, Garden GA, Gill N, Rueb U, Libby RT, Schultz C, et al. Bergmann glia expression of polyglutamine-expanded ataxin-7 produces neurodegeneration by impairing glutamate transport. Nat Neurosci. 2006;9:1302–11.

    Article  PubMed  CAS  Google Scholar 

  28. Cummings CJ, Mancini MA, Antalffy B, DeFranco DB, Orr HT, Zoghbi HY. Chaperone suppression of aggregation and altered subcellular proteasome localization imply protein misfolding in SCA1. Nat Genet. 1998;19:148–54.

    Article  PubMed  CAS  Google Scholar 

  29. Emamian ES, Kaytor MD, Duvick LA, Zu T, Tousey SK, Zoghbi HY, et al. Serine 776 of ataxin-1 is critical for polyglutamine-induced disease in SCA1 transgenic mice. Neuron. 2003;38:375–87.

    Article  PubMed  CAS  Google Scholar 

  30. Chen HK, Fernandez-Funez P, Acevedo SF, et al. Interaction of Akt-phosphorylated ataxin-1 with 14-3-3 mediates neurodegeneration in spinocerebellar ataxia type 1. Cell. 2003;113:457–68.

    Article  PubMed  CAS  Google Scholar 

  31. Liu Y, Buck DC, Neve KA. Novel interaction of the dopamine D2 receptor and the Ca2+ binding protein S100B: role in D2 receptor function. Mol Pharmacol. 2008;74:371–8.

    Article  PubMed  CAS  Google Scholar 

  32. Parfitt DA, Michael GJ, Vermeulen EG, Prodromou NV, Webb TR, Gallo JM, et al. The ataxia protein sacsin is a functional cochaperone that protects against polyglutamine-expanded ataxin-1. Hum Mol Genet. 2009;18:1556–65.

    Article  PubMed  CAS  Google Scholar 

  33. Hearst SM, Lopez ME, Shao Q, Liu Y, Vig PJ. Dopamine D2 receptor signaling modulates mutant ataxin-1 S776 phosphorylation and aggregation. J Neurochem. 2010;114:706–16.

    Article  PubMed  CAS  Google Scholar 

  34. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 2001;25:402–8.

    Article  PubMed  CAS  Google Scholar 

  35. Vig PJS, Subramony SH, D’Souza DR, Wei J, Lopez ME. Intranasal administration of IGF-I improves behavior and Purkinje cell pathology in SCA1 mice. Brain Res Bull. 2006;69:573–9.

    Article  PubMed  CAS  Google Scholar 

  36. Donato R, Sorci G, Riuzzi F, Arcuri C, Bianchi R, Brozzi F, et al. S100B's double life: intracellular regulator and extracellular signal. Biochim Biophys Acta. 2009;1793:1008–22.

    Article  PubMed  CAS  Google Scholar 

  37. Klement IA, Skinner PJ, Kaytor MD, Yi H, Hersch SM, Clark HB, et al. Ataxin-1 nuclear localization and aggregation: role in polyglutamine-induced disease in SCA1 transgenic mice. Cell. 1998;95:41–53.

    Article  PubMed  CAS  Google Scholar 

  38. Ivanenkov VV, Jamieson Jr GA, Gruenstein E, Dimlich RV. Characterization of S-100b binding epitopes. Identification of a novel target, the actin capping protein, CapZ. J Biol Chem. 1995;270:14651–8.

    Article  PubMed  CAS  Google Scholar 

  39. Bianchi R, Garbuglia M, Verzini M, Giambanco I, Ivanenkov VV, Dimlich RV, et al. S-100 (alpha and beta) binding peptide (TRTK-12) blocks S-100/GFAP interaction: identification of a putative S-100 target epitope within the head domain of GFAP. Biochim Biophys Acta. 1996;1313:258–67.

    Article  PubMed  Google Scholar 

  40. Charpentier TH, Thompson LE, Liriano MA, et al. The effects of CapZ peptide (TRTK-12) binding to S100B-Ca2+ as examined by NMR and X-ray crystallography. J Mol Biol. 2010;396:1227–43.

    Article  PubMed  CAS  Google Scholar 

  41. Thorne RG, Pronk GJ, Padmanabhan V, Frey 2nd WH. Delivery of insulin-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration. Neuroscience. 2004;127:481–96.

    Article  PubMed  CAS  Google Scholar 

  42. Basco E, Hajos F, Fulop Z. Proliferation of Bergmann-glia in the developing rat cerebellum. Anat Embryol (Berl). 1977;151:219–22.

    Article  CAS  Google Scholar 

  43. Shiga T, Ichikawa M, Hirata Y. Spatial and temporal pattern of postnatal proliferation of Bergmann glial cells in rat cerebellum: an autoradiographic study. Anat Embryol (Berl). 1983;167:203–11.

    Article  CAS  Google Scholar 

  44. Gaiano N, Fishell G. The role of notch in promoting glial and neural stem cell fates. Annu Rev Neurosci. 2002;25:471–90.

    Article  PubMed  CAS  Google Scholar 

  45. Ellis EF, Willoughby KA, Sparks SA, Chen T. S100B protein is released from rat neonatal neurons, astrocytes, and microglia by in vitro trauma and anti-S100 increases trauma-induced delayed neuronal injury and negates the protective effect of exogenous S100B on neurons. J Neurochem. 2007;101:1463–70.

    Article  PubMed  CAS  Google Scholar 

  46. Gerlach R, Demel G, König HG, Gross U, Prehn JH, Raabe A, et al. Active secretion of S100B from astrocytes during metabolic stress. Neuroscience. 2006;141:1697–701.

    Article  PubMed  CAS  Google Scholar 

  47. Watase K, Weeber EJ, Xu B, Antalffy B, Yuva-Paylor L, Hashimoto K, et al. A long CAG repeat in the mouse Sca1 locus replicates SCA1 features and reveals the impact of protein solubility on selective neurodegeneration. Neuron. 2002;34:905–19.

    Article  PubMed  CAS  Google Scholar 

  48. Lin X, Antalffy B, Kang D, Orr HT, Zogbi HY. Polyglutamine expansion down-regulates specific neuronal genes before pathologic changes in SCA1. Nat Neurosci. 2000;3:157–63.

    Article  PubMed  CAS  Google Scholar 

  49. Vig PJS, Subramony SH, Qin Z, McDaniel DO, Fratkin J. Relationship between ataxin-1 nuclear inclusions and Purkinje cell specific proteins in SCA-1 transgenic mice. J Neurol Sci. 2000;174:100–10.

    Article  PubMed  CAS  Google Scholar 

  50. Goold R, Hubank M, Hunt A, Holton J, Menon RP, Revesz T, et al. Down-regulation of the dopamine receptor D2 in mice lacking ataxin-1. Hum Mol Genet. 2007;17:2122–34.

    Article  Google Scholar 

  51. Tubaro C, Arcuri C, Giambanco I, Donato R. S100B protein in myoblasts modulates myogenic differentiation via NF-κB-dependent inhibition of MyoD expression. J Cell Physiol. 2010;223:270–82.

    PubMed  CAS  Google Scholar 

  52. Saito T, Ikeda T, Nakamura K, Chung U-I, Kawaguchi H. S100A1 and S100B, transcriptional targets of SOX trio, inhibit terminal differentiation of chondrocytes. EMBO Rep. 2007;8:504–9.

    Article  PubMed  CAS  Google Scholar 

  53. Brozzi F, Arcuri C, Giambanco I, Donato R. S100B protein regulates astrocyte shape and migration via interaction with Src kinase: implications for astrocyte development, activation and tumor growth. J Biol Chem. 2009;284:8797–811.

    Article  PubMed  CAS  Google Scholar 

  54. Sorci G, Bianchi R, Riuzzi F, Tubaro C, Arcuri C, Giambanco I, Donato R. S100B protein, a damage-associated molecular pattern protein in the brain and heart, and beyond. Cardiovasc Psychiatry Neurol. 2011. pii: 656481.

  55. Stegert MR, Tamaskovic R, Bichsel SJ, Hergovich A, Hemmings BA. Regulation of NDR2 protein kinase by multi-site phosphorylation and the S100B calcium-binding protein. J Biol Chem. 2004;279:23806–12.

    Article  PubMed  CAS  Google Scholar 

  56. Stork O, Zhdanov A, Kudersky A, Yoshikawa T, Obata K, Pape HC. Neuronal functions of the novel serine/threonine kinase Ndr2. J Biol Chem. 2004;279:45773–81.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgment

This work was supported in part by a grant from the National Ataxia Foundation.

Conflict of Interest

The authors declare to have no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Neurology, University of Mississippi Medical Center, 2500 North State Street, Jackson, MS, 39216, USA

    Parminder J. S. Vig, Scoty Hearst, Qingmei Shao, Mariper E. Lopez, Henry A. Murphy II & Eshan Safaya

  2. Department of Biochemistry, University of Mississippi Medical Center, Jackson, MS, 39216, USA

    Parminder J. S. Vig & Scoty Hearst

Authors
  1. Parminder J. S. Vig
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Scoty Hearst
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Qingmei Shao
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mariper E. Lopez
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Henry A. Murphy II
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Eshan Safaya
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Parminder J. S. Vig.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Vig, P.J.S., Hearst, S., Shao, Q. et al. Glial S100B Protein Modulates Mutant Ataxin-1 Aggregation and Toxicity: TRTK12 Peptide, a Potential Candidate for SCA1 Therapy. Cerebellum 10, 254–266 (2011). https://doi.org/10.1007/s12311-011-0262-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12311-011-0262-5

Keywords

Search

Navigation